Kang YK - Search Results

1

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators. Zhu AX, et al. Among authors: kang yk. Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18. Lancet Oncol. 2019. PMID: 30665869 Clinical Trial.

2

Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report.

Lee JH, Lee JH, Ahn JH, Bahng H, Kim TW, Kang YK, Lee KH, Kim JC, Yu CS, Kim JH, Ahn SD, Kim WK, Kim SH, Lee JS. Lee JH, et al. Among authors: kang yk. J Clin Oncol. 2002 Apr 1;20(7):1751-8. doi: 10.1200/JCO.2002.07.037. J Clin Oncol. 2002. PMID: 11919231 Clinical Trial.

3

Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin.

Ahn JH, Kim TW, Lee JH, Min YJ, Kim JG, Kim JC, Yu CS, Kim WK, Kang YK, Lee JS. Ahn JH, et al. Among authors: kang yk. Am J Clin Oncol. 2003 Feb;26(1):98-102. doi: 10.1097/01.COC.0000017089.68491.1F. Am J Clin Oncol. 2003. PMID: 12576934 Clinical Trial.

4

Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.

Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Sohn HJ, Lee JS, Kang YK. Lee JL, et al. Among authors: kang hj, kang yk. Jpn J Clin Oncol. 2006 Nov;36(11):704-11. doi: 10.1093/jjco/hyl088. Epub 2006 Oct 26. Jpn J Clin Oncol. 2006. PMID: 17068083

5

Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.

Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Kim WK, Lee JS, Kang YK. Lee SS, et al. Among authors: kang hj, kang yk. Jpn J Clin Oncol. 2007 Jan;37(1):30-7. doi: 10.1093/jjco/hyl134. Jpn J Clin Oncol. 2007. PMID: 17272321

6

Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.

Kim JG, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH, Kang YK. Kim JG, et al. Among authors: kang yk. Cancer Chemother Pharmacol. 2008 Feb;61(2):301-7. doi: 10.1007/s00280-007-0476-x. Epub 2007 Apr 12. Cancer Chemother Pharmacol. 2008. PMID: 17429626

7

Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.

Park YH, Lee JL, Ryoo BY, Ryu MH, Yang SH, Kim BS, Shin DB, Chang HM, Kim TW, Yuh YJ, Kang YK. Park YH, et al. Among authors: kang yk. Cancer Chemother Pharmacol. 2008 Apr;61(4):623-9. doi: 10.1007/s00280-007-0515-7. Epub 2007 May 24. Cancer Chemother Pharmacol. 2008. PMID: 17522863 Clinical Trial.

8

Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial.

Kim YH, Yamaguchi K, Bang YJ, Takiuchi H, Kang WK, Sato A, Kang YK, Sakamoto J, Abe C, Sakata Y. Kim YH, et al. Among authors: kang wk, kang yk. Jpn J Clin Oncol. 2007 Jul;37(7):501-8. doi: 10.1093/jjco/hym054. Epub 2007 Aug 2. Jpn J Clin Oncol. 2007. PMID: 17673470 Clinical Trial.

9

Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: a retrospective analysis.

Lee JL, Ryu MH, Chang HM, Kim TW, Lee SS, Sym SJ, Kim MK, Kim KM, Lee JS, Kang YK. Lee JL, et al. Among authors: kang yk. J Gastroenterol Hepatol. 2008 May;23(5):811-6. doi: 10.1111/j.1440-1746.2007.05213.x. Epub 2007 Nov 6. J Gastroenterol Hepatol. 2008. PMID: 17995941

10

Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.

Jo JC, Lee JL, Ryu MH, Sym SJ, Lee SS, Chang HM, Kim TW, Lee JS, Kang YK. Jo JC, et al. Among authors: kang yk. Jpn J Clin Oncol. 2007 Dec;37(12):936-41. doi: 10.1093/jjco/hym123. Jpn J Clin Oncol. 2007. PMID: 18211985

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

791 results

Search Page

Filters